QSAR modeling of in vitro inhibition of cytochrome P450 3A4

Journal of Chemical Information and Modeling

Volumn 46, Issue 5, 2006, Pages 2125-2134

  Mao, Boryeu ^a   Gozalbes, Rafael ^b   Barbosa, Frédérique ^b   Migeon, Jacques ^a   Merrick, Sandra ^a   Kamm, Kelly ^a   Wong, Eric ^a   Costales, Chester ^a   Shi, Wei ^a   Wu, Cheryl ^a   Froloff, Nicolas ^b  

^a Cerep   (United States)

^b CEREP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; DATA STRUCTURES; DRUG INTERACTIONS; DRUG PRODUCTS; ENZYME INHIBITION; PHARMACODYNAMICS;

BENZYLOXYRESORUFINS; CHEMICAL LIBRARIES; CYTOCHROME P450; MULTIPLE PHARMACOPHORE HYPOTHESIS (MPH);

ENZYMES;

CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33750360495     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci0600915     Document Type: Article

References (50)

1. Coon, M. J. Cytochrome P450: Nature's Most Versatile Biological Catalyst. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 1-25.
2. Hardman, J. G.; Limbird, L. E.; Gilman, A. G. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; McGraw Hill: New York, 2001; p 15.
3. Rendic, S. Summary of Information on Human CYP Enzymes: Human P450 Metabolism Data. Drug Metab. Rev. 2002, 34, 83-448.
4. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Inter-individual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
5. Furukawa, M.; Nishimura, M.; Ogino, D.; Chiba, R.; Ikai, I.; Ueda, N.; Naito, S.; Kuribayashi, S.; Moustafa, M. A.; Uchida, T.; Sawada, H.; Kamataki, T.; Funae, Y.; Fukumoto, M. Cytochrome P450 Gene Expression Levels in Peripheral Blood Mononuclear Cells in Comparison with the Liver. Cancer Sci. 2004, 95, 520-529.
6. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K. R. Activation of CYP3A4: Evidence for the Simultaneous Binding of Two Substrates in a Cytochrome P450 Active Site. Biochemistry 1994, 33, 6450-6455.
7. Wang, R. W.; Newton, D. J.; Liu, N.: Atkins, W. M.; Lu, A. Y. H. Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns are Substrate-Dependent. Drug Metab. Dispos. 2000, 28, 360-366.
8. Atkins, W. M.; Wang, R. W.; Lu, A. Y. H. Allosteric Behavior in Cytochrome P450-Dependent in Vitro Drug-Drug Interactions: A Prospective Based on Conformational Dynamics. Chem. Res. Toxicol. 2002, 14, 338-347.
9. Ekins, S.; Stresser, D. M.; Williams, J. A. In vitro and Pharmacophore Insights into CYP3A Enzymes. Trends Pharmacol. Sci. 2003, 24, 161-166.
10. Koley, A. P.; Robinson, R. C.; Markowitz, A.; Friedman, F. K. Drug-Drug Interactions: Effect of Quinidine on Nifedipine Binding to Human Cytochrome P450 3A4. Biochem. Pharmacol. 1997, 53, 455-460.
11. Domanski, T. L.; He, Y.-A.; Harlow, G. R.; Halpert, J. R. Dual Role of Human Cytochrome P450 3A4 Residue Phe-304 in Substrate Specificity and Cooperativity. J. Pharmacol. Exp. Ther. 2000, 293, 585-591.
12. Schrag, M. L.; Wienkers, L. C. Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding Domains. Arch. Biochem. Biophys. 2001, 391, 49-55.
13. Lu, P.; Lin, Y.; Rodrigues, A. D.; Rushmore, T. H.: Baillie, T. A.; Shou, M. Testosterone, 7-Benzyloxyquinoline, and 7-Benzyloxy-4-trifluoromethyl- coumarin Bind to Different Domains within the Active Site of Cytochrome P450 3A4. Drug Metab. Dispos. 2001, 29, 1473-1479.
14. Kenworthy, K. E.; Clarke, S. E.; Andrews, J.; Houston, J. B. Multisite Kinetic Models for CYP3A4: Simultaneous Activation and Inhibition of Diazepam and Testosterone Metabolism. Drug Metab. Dispos. 2001, 29, 1644-1651.
15. Shou, M.; Dai, R.; Cui, D.; Korzekwa, K. R.; Baillie, T. A.; Rushmore, T. H. A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4. J. Biol. Chem. 2001, 276, 2256-2262.
16. Hosea, N. A.; Miller, G. P.; Guengerich, F. P. Elucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4. Biochemistry 2000, 39, 5929-5939.
17. Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution. J. Biol. Chem. 2004, 279, 36091-36094.
18. Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove, H. C.; Day. P. J.; Vonrhein, C.; Tickle, I. J.; Jhoti, H. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone. Science 2004, 305, 683-686.
19. Krejsa. C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME Properties and Side Effects: The BioPrint Approach. (BioPrint is a registered trademark of Cerep). Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480.
20. Froloff, N.; Hamon, V.; Dupuis, P.; Otto-Bruc, A.; Mao, B.; Merrick, S.: Migeon, J. Construction of a Homogeneous and Informative in Vitro Profiling Database for Anticipating the Clinical Effects of Drugs. In Chemogenomics Knowledge-based Approaches to Drug Discovery, Jacoby, E., Ed.; Imperial College Press: London. 2006; Chapter 8, pp 175-206.
21. de Groot, M. J.; Ekins, S. Pharmacophore Modeling of Cytochromes P450. Adv. Drug Delivery Rev. 2002, 54, 367-383.
22. Liu, J.; Pan, D.; Tseng, Y.: Hopfinger, A. J. 4D-QSAR Analysis of a Series of Antifungal P450 Inhibitors and 3D-Pharmacophore Comparisons as a Function of Alignment. J. Chem. Inf. Comput. Sci. 2003, 43, 2170-2179.
23. de Groot, M. J.; Kirton, S. B.; Sutcliffe, M. J. In Silico Methods for Predicting Ligand Binding Determinants of Cytochromes P450. Curr. Top. Med. Chem. 2004, 4, 1803-1824.
24. Afzelius, L.; Zamora, I.; Masimirembwa, C. M.; Karlen, A.; Andersson, T. B.: Mecucci, S.; Baroni, M.: Cruciani, G. Conformer- and Alignment-Independent Model for Predicting Structurally Diverse Competitive CYP2C9 Inhibitors. J. Med. Chem. 2004, 47, 907-914.
25. Gozalbes, R.; Barbosa, F.; Froloff, N.; Horvath, D. The BioPrint Approach for the Evaluation of ADMET Properties: Application to the Prediction of Cytochrome P450 2D6 Inhibition. In Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies; Testa, B., Krämer, S. D., Wunderli-Allenspach, H., Folkers. G., Eds.; VHCA: Zürich, Switzerland, 2006; pp 395-415.
26. Wanchana, S.; Yamashita, F.; Hashida, M. QSAR Analysis of the Inhibition of Recombinant CYP 3A4 Activity by Structurally Diverse Compounds Using a Genetic Algorithm-Combined Partial Least Squares Method. Pharm. Res. 2003, 20, 1401-1408.
27. Stresser, D. M.; Blanchard, A. P.; Turner, S. D.; Erve, J. L.; Dandeneau, A. A.; Miller, V. P.; Crespi, C. L. Substrate-dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates. Drug Metab. Dispos. 2000, 25, 1440-1448.
28. Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F. J.; Tsutsui, M. Specificity of Substrate and Inhibitor Probes for Cytochrome P450s; Evaluation of in Vitro Metabolism using cDNA-Expressed Human P450s and Human Liver Microsomes. Xenobiotica 1996, 26, 681-693.
29. Horvath, D. High Throughput Conformational Sampling and Fuzzy Similarity Metrics: A Novel Approach to Similarity Searching and Focused Combinatorial Library Design and Its Role in the Drug Discovery Laboratory. In Combinatorial Library Design and Evaluation; Chose, A. K., Viswanadhan, V. N., Eds.; Marcel Dekker Inc.: New York, 2001; pp 429-471.
30. Gozalbes, R.; Rolland, C.; Nicolai, E.; Paugam, M.-F.; Coussy, L.; Horvath, D.: Barbpsa, F.; Mao, B.; Revah, F.; Froloff, N. QSAR Strategy and Experimental Validation for the Development of a GPCR Focused Library. QSAR Comb. Sci. 2005, 24, 508-516.
31. Kier, L. H.; Hall, L. B. The Molecular Connectivity Chi Indexes and Kappa Shape Indexes in Structure-Property Modeling. In Reviews in Computational Chemistry II; Lipkowitz, K. B., Boyd, D. B., Eds.; VCH Publishers: New York, 1991; pp 367-422.
32. Kier, L. H.; Hall, L. B. The Molecular Description; Wiley: New York, 1999.
33. Kier, L. H.; Hall, L. B. Molecular Connectivity in Chemistry and Drug Research; Academic Press: New York, 1976.
34. Tordeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiley-VCH: Weinheim, Germany, 2000.
35. Yoshida, F.; Topliss, J. G. QSAR Model for Drug Human Oral Bioavailability. J. Med. Chem. 2000, 43, 2575-2585.
36. Horvath, D.; Jeandenans, C. Neighborhood Behavior of in Silico Structural Spaces with Respect to in Vitro Activity Spaces-A Novel Understanding of the Molecular Similarity Principle in the Context of Multiple Receptor Binding Profiles. J. Chem. Inf. Comput. Sci. 2003, 43, 680-690.
37. Horvath, D.; Jeandenans, C. Neighborhood Behavior of in Silico Structural Spaces with Respect to in Vitro Activity Spaces-A Benchmark for Neighborhood Behavior Assessment of Different in Silico Similarity Metrics. J. Chem. Inf. Comput. Sci. 2003, 43, 691-698.
38. Chang, C.-C.; Lin, C.-J. LIBSVM: A Library for Support Vector Machines; 2001. Software available at http://www.csie.ntu.edu.tw/~cjlin/libsvm (accessed Apr 2005).
39. Byvatov, E.; Schneider, G. SVM-Based Feature Selection for Characterization of Focused Compound Collections. J. Chem. Inf. Comput. Sci. 2004, 44, 993-999.
40. Yap, C. W.; Chen, Y. Z. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. J. Chem. Inf. Model. 2005, 45, 982-992.
41. Strobl, G. R.; von Kruedener, S.; Stockigt, J.; Guengerich, F. P.; Wolff, T. Development of a Pharmacophore for Inhibition of Human Liver Cytochrome P-450 2D6: Molecular Modeling and Inhibition Studies. J. Med. Chem. 1993, 36, 1136-1145.
42. Susnow, R. G.; Dixon, S. L. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition. J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
43. Ekins, S.; Berbaum, J.; Harrison, R. K. Generation and Validation of Rapid Computational Filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 2003, 31, 1077-1080.
44. Kriegl, J. M.; Eriksson, L.; Arnhold, T.; Beck, B.; Johansson, E.; Fox, T. Multivariate Modeling of Cytochrome P450 3A4 Inhibition. Eur. J. Pharm. Sci. 2005, 24, 451-463.
45. Arimoto, R.; Prasad, M. A.; Gifford, E. Development of CYP3A4 Inhibition Model: Comparison of Machine-Learning Techniques and Molecular Descriptors. J. Biomol. Screen. 2005, 10, 197-205.
46. 2. Am. Stat. 1985, 39, 279-285.
47. Ekins, S.; Bravi, G.; Wikel, J. H.; Wrighton, S. A. Three-Dimensional- Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3A4 Substrates. Drug Metab. Dispos. 1999, 291, 424-433.
48. Stresser, D. M.; Turner, S. D.; Blanchard, A. P.; Miller, V. P.; Crespi, C. L. Cytochrome P450 Fluorometric Substrates: Identification of Isoform-Selective Probes for Rat CYP2D2 and Human CYP3A4. Drug Metab. Dispos. 2002, 30, 845-852.
49. Fowler, S. M.; Taylor, J. M.; Friedberg, T.; Wolf, C. R.; Riley, R. J. CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211. Drug Metab. Dispos. 2002, 30, 452-456.
50. Zar, J. H. Biostatistical Analysis, 3rd ed.; Prentice-Hall: Upper Saddle River, NJ, 1996; pp 415-418.